ON CLINICAL MILESTONE - CYTOMED THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN ITS FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ALLOGENEIC CAR-GAMMA DELTA T CELL THERAPY IN PATIENTS WITH ADVANCED SOLID TUM ...

Immunotherapies that use combination approaches are now emerging. Recent research from University College London demonstrated how engineered immune cells called gamma-delta T-cells could act as ...

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma ...

targeting metastatic clear cell renal cell carcinoma, marking a significant step in utilizing gamma delta CAR T cell therapies for solid tumors. The company also began dosing a lupus nephritis patient ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Pan Am — the airline considered to be among the best of the world during travel’s so-called Golden Age — reportedly at one ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...

Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, ...

My doctor didn’t explain all the risks of my surgery, and I ended up with complications that I wasn’t prepared for. What can ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...

In the world of cell therapy, Silicon Valley has long recognized that technological innovation is the key to solving ...